U018 Innovative and Advanced Management of Biologics and Small Molecule Inhibitors in Hidradenitis Suppurativa and Beyond
DESCRIPTION
This session will serve to help the general and medical dermatologist with management and utilization of biologics for HS and other challenging and refractory inflammatory skin conditions from therapeutic drug monitoring to management of paradoxical rashes and JAKne on biologics; from determining treatment in patients with concomitant chronic infections (TB, HIV, and HBV), to managing disease when new infections emerge. The session will review medications in the pipeline for HS and evidence for utilization of dual biologics/small molecules along with safety and monitoring.
LEARNING OBJECTIVES
Outline methods and reasoning behind therapeutic drug monitoring (TDM) in the treatment and management of patients with severe hidradenitis suppurativa with special attention to recent innovations in this arena.
Summarize the management of biologic toxicities in patients with HS with specific discussion of paradoxical skin reactions, infection risk, screening lab abnormalities (such as hepatitis and TB testing positivity), lupus-like reactions, JAKne, and oral/esophageal candidiasis.
Identify innovations in the HS biologic/small molecule pipeline including both new therapeutics AND timing and utilization of combined biologic therapies for refractory disease.
SCHEDULE
3:30 PM
Infectious risk and Lab monitoring in Advanced Biologics
Julia Mhlaba Riley, MD, FAAD
3:40 PM
Therapeutic Drug Monitoring in HS and Beyond
Stella Chen, MD, FAAD
3:50 PM
Paradoxical Rashes and 'JAKne' Risk factors and Management
Alexandra P Charrow, MD, FAAD
4:00 PM
Dual Biologics and Small Molecule Inhibitors
Jennifer Lin Hsiao, MD, FAAD
4:10 PM
Biologics and SMI Pipeline in HS
Leandra Alicia Barnes, MD, FAAD
4:20 PM
Q and A
DIRECTOR
Alexandra P Charrow, MD, FAAD
SPEAKERS
Leandra Alicia Barnes, MD, FAAD
Stella Chen, MD, FAAD
Jennifer Lin Hsiao, MD, FAAD
Julia Mhlaba Riley, MD, FAAD
DISCLOSURES
Leandra Alicia Barnes, MD, FAAD
No financial relationships exist with ineligible companies.
Alexandra P Charrow, MD, FAAD
Avalo – Consultant (1099 relationship)(Fees); Dermatology Foundation – Investigator(Grants/Research Funding); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received), Investigator(Grants/Research Funding); Incyte Corporation – Advisory Board(Fees), Investigator(No Compensation Received); Insmed – Investigator(No Compensation Received); Insmed Incorporated – Investigator(No Compensation Received); Novartis Pharmaceuticals Corp. – Advisory Board(Fees); Q32 Bio Inc. – Consultant (1099 relationship)(No Compensation Received); Sonoma Biotherapeutics – Investigator(No Compensation Received); UCB Pharma – Advisory Board(Honoraria); Wedbush Securities – Consultant (1099 relationship)(Honoraria);
Stella Chen, MD, FAAD
No financial relationships exist with ineligible companies.
Jennifer Lin Hsiao, MD, FAAD
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Insmed – Consultant (1099 relationship)(Fees); Leo Pharma – Consultant (1099 relationship)(Fees); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees), Speaker(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Consultant(Fees), Speaker(Fees);
Julia Mhlaba Riley, MD, FAAD
AbbVie – Investigator(Fees); Incyte Corporation – Investigator(Fees); MoonLake Immunotherapeutics – Investigator(Fees); Novartis – Investigator(Fees); UCB – Advisory Board(Fees);